In the video below, Fool analysts David Williamson and Max Macaluso discuss drugmaker Dendreon (NASDAQOTH:DNDNQ) as a possible takeover target in 2013.

While hope of a buyout has diminished as Dendreon's struggles mounted, the possibility still exists. However, there is one additional hurdle that might keep big pharma away from Dendreon, which investors are not talking about.

David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavidMax Macaluso has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.